Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.76 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | SLC26A4 | O43511 | 7/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965650 | 0.88 | KDM4E (0.64) | POLBSMN1; SMN2GAASLC26A4TSHR | |
| SCHEMBL24470997 | 0.86 | SLC26A4 (0.80) | POLBSLC26A4KMT2AMEN1HTT | |
| SCHEMBL29713047 | 0.84 | SLC26A4 (0.77) | POLBSLC26A4KMT2AMEN1HTT | |
| SCHEMBL24470995 | 0.84 | SLC26A4 (0.77) | POLBSLC26A4KMT2AMEN1HTT | |
| SCHEMBL3976556 | 0.84 | SLC26A4 (0.69) | POLBSLC26A4TSHRKMT2AMEN1 | |
| SCHEMBL16654822 | 0.82 | SMN1; SMN2 (0.68) | POLBSMN1; SMN2GAATSHRKMT2A | |
| SCHEMBL28654740 | 0.82 | PTGS2 (0.85) | POLBSMN1; SMN2GAATSHRLMNA | |
| SCHEMBL28649551 | 0.81 | GAA (0.69) | POLBSMN1; SMN2GAATSHRKMT2A | |
| SCHEMBL30664708 | 0.80 | SLC26A4 (0.65) | POLBSMN1; SMN2GAASLC26A4TSHR | |
| SCHEMBL26676568 | 0.80 | SLC26A4 (0.65) | POLBSMN1; SMN2GAASLC26A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113698375-A | Synthesis method of 4-cyclohexylimine methyl substituted benzofuran derivative | 八叶草健康产业研究院(厦门)有限公司 | 2021-11-26 | — | — | CN | claimed |
| EP-3597186-B1 | MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE | US HEALTH (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113698375-A | Synthesis method of 4-cyclohexylimine methyl substituted benzofuran derivative | 八叶草健康产业研究院(厦门)有限公司 | 2021-11-26 | — | — | CN | disclosed |
| CN-113698375-A | Synthesis method of 4-cyclohexylimine methyl substituted benzofuran derivative | 八叶草健康产业研究院(厦门)有限公司 | 2021-11-26 | — | — | CN | disclosed |
| US-11014902-B2 | MYC G-quadruplex stabilizing small molecules and their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-05-25 | — | — | US | disclosed |
| US-11014902-B2 | MYC G-quadruplex stabilizing small molecules and their use | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2021-05-25 | — | — | US | disclosed |
| US-20200308128-A1 | MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2020-10-01 | — | — | US | disclosed |
| US-20200308128-A1 | MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC (US) | 2020-10-01 | — | — | US | disclosed |
| US-10604499-B2 | MYC G-quadruplex stabilizing small molecules and their use | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3242661-B1 | MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE | US HEALTH (US) | 2019-08-21 | — | — | EP | disclosed |
| US-8163916-B2 | 4-(6-Chloronicotinoyloxy)- or 4-(benzothien-5-ylcarbamoyloxy)-1-azatricyclo(3.3.1.1(3,7)decane;interacting selectively with nicotinic receptors alpha 7 and/or alpha 4 beta 2;cognition activators, Alzheimer's disease; dementia of AIDS, Lewey bodies, Down's; Pick's disease, smoking abuse; analgesics | ABBOTT LABORATORIES (US) | 2012-04-24 | — | — | US | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| EP-2129672-B1 | AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LAB (US) | 2011-05-18 | — | — | EP | disclosed |
| EP-2129672-A1 | AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF | Abbott Laboratories (US) | 2009-12-09 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| US-20080255178-A1 | Azaadamantane Ester and Carbamate Derivatives and Methods of Use Thereof | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | US | disclosed |
| WO-2008118742-A1 | AZAADAMANTANE ESTER AND CARBAMATE DERIVATIVES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2008-10-02 | — | — | WO | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255178-A1 | Azaadamantane Ester and Carbamate Derivatives and Methods of Use Thereof | CYP51A1, ALKBH5, AZI2 | POLB 2007/4885SMN1; SMN2 3966/4885GAA 1148/4885 |
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | POLB 2936/4885SMN1; SMN2 3624/4885GAA 4732/4885 |
| US-10604499-B2 | MYC G-quadruplex stabilizing small molecules and their use | MYC, MYCBP, MYCBP2 | POLB 260/4885SMN1; SMN2 1636/4885GAA 2049/4885 |
| US-20200308128-A1 | MYC G-QUADRUPLEX STABILIZING SMALL MOLECULES AND THEIR USE | MYC, MYCBP, MYCBP2 | POLB 260/4885SMN1; SMN2 1636/4885GAA 2049/4885 |
| US-11014902-B2 | MYC G-quadruplex stabilizing small molecules and their use | MYC, MYCBP, MYCBP2 | POLB 260/4885SMN1; SMN2 1636/4885GAA 2049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.